COVID-19: Get Vaccinated. Get Tested. Visitor Guidelines. Please use ER for Emergency Issues only.


  • A041501 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
  • A041701  A Randomized Phase II/III Study of Conventional chemotherapy +/- Uproleselan in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction chemotherapy
  • A041702 A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
  • A041703 A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
  • ACCL16N1CD Cancer Care Delivery in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia
  • EA9161 A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
  • EA9181 A Phase III Randomized Trial of Steroids + TKI Induction with Chemotherapy or Blinatumombab for Newly Diagnosed BCR-ABL-Positive ALL in adults
  • S1712  Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating patients with Chronic Myeloid Leukemia